1. Home /
    2. Altai Protocol Library /
  2. New Indication: Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer

New Indication: Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer
Study:
  • A Phase III Multi-center, Randomized, Open-label trial (NATALEE)
  • Hormone Receptor-positive, HER2-negative Early Breast Cancer (Stage IIa-III)
  • Ribociclib (400 mg/day) + ET (n=2549) vs ET (n=2552)
Efficacy:
  • 3-year iDFS: 90.4% vs 87.1%, HR:0.74, p=0.0014
Safety:
  • Grade≥3: Unspcified

Journal of Clinical Oncology 2023 41:17_suppl, LBA500-LBA500

Slamon Dennis J et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial

http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA500

Reviewed by Elvin CHALABİYEV, MD on JUL 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More